GABAergic signaling beyond synapses: an emerging target for cancer therapy

Trends Cell Biol. 2023 May;33(5):403-412. doi: 10.1016/j.tcb.2022.08.004. Epub 2022 Sep 13.

Abstract

Traditionally, γ-aminobutyric acid (GABA) is best known for its role as a primary inhibitory neurotransmitter reducing neuronal excitability in the mammalian central nervous system (CNS), thereby producing calming effects. However, an emerging body of data now supports a function for GABA beyond neurotransmission as a potent factor regulating cancer cell growth and metastasis, as well as the antitumor immune response, by shaping the tumor microenvironment (TME). Here, we review the current knowledge on GABA's effects on the function of tumor cells, tumor-immune interactions, and the underlying molecular mechanisms. Since altered GABAergic signaling is now recognized as a feature of certain types of solid tumors, we also discuss the potential of repurposing existing GABAergic agents as a new class of anticancer therapy.

Keywords: GABAergic signaling; antitumor immunity; cancer therapy; metastasis; tumor growth.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Humans
  • Mammals / metabolism
  • Neoplasms* / drug therapy
  • Neoplasms* / metabolism
  • Neurons / metabolism
  • Neurotransmitter Agents
  • Signal Transduction / physiology
  • Synapses / metabolism
  • gamma-Aminobutyric Acid* / metabolism

Substances

  • gamma-Aminobutyric Acid
  • Neurotransmitter Agents